



Genetic Contribution to the Divergence in Type 1 Diabetes Risk Between Children From the General Population and Children From Affected Families

Markus Hippich,¹ Andreas Beyerlein,^{1,2} William A. Hagopian,³ Jeffrey P. Krischer,⁴ Kendra Vehik,⁴ Jan Knoop,¹ Christiane Winker,^{1,5} Jorma Toppari,⁶ Åke Lernmark,⁷ Marian J. Rewers,⁸ Andrea K. Steck,⁸ Jin-Xiong She,⁹ Beena Akolkar,¹⁰ Catherine C. Robertson,¹¹ Suna Onengut-Gumuscu,¹¹ Stephen S. Rich,¹¹ Ezio Bonifacio,^{5,12} Anette-G. Ziegler,^{1,2,5} and the TEDDY Study Group*

Diabetes 2019;68:847–857 | <https://doi.org/10.2337/db18-0882>

The risk for autoimmunity and subsequently type 1 diabetes is 10-fold higher in children with a first-degree family history of type 1 diabetes (FDR children) than in children in the general population (GP children). We analyzed children with high-risk HLA genotypes ($n = 4,573$) in the longitudinal TEDDY birth cohort to determine how much of the divergent risk is attributable to genetic enrichment in affected families. Enrichment for susceptible genotypes of multiple type 1 diabetes-associated genes and a novel risk gene, *BTNL2*, was identified in FDR children compared with GP children. After correction for genetic enrichment, the risks in the FDR and GP children converged but were not identical for multiple islet autoantibodies (hazard ratio [HR] 2.26 [95% CI 1.6–3.02]) and for diabetes (HR 2.92 [95% CI 2.05–4.16]). Convergence varied depending upon the degree of genetic susceptibility. Risks were similar in the highest genetic susceptibility group for multiple islet autoantibodies (14.3% vs .12.7%) and diabetes (4.8% vs. 4.1%) and were up to 5.8-fold divergent for children in the lowest genetic susceptibility group, decreasing

incrementally in GP children but not in FDR children. These findings suggest that additional factors enriched within affected families preferentially increase the risk of autoimmunity and type 1 diabetes in lower genetic susceptibility strata.

Type 1 diabetes has a presymptomatic phase that often starts with the appearance of autoantibodies to pancreatic islet cell antigens (1). The development of islet autoantibodies is strongly influenced by HLA DR and DQ genotypes, with smaller contributions from many other genes (2–4). Children with a first-degree family history of type 1 diabetes (FDR children) have a higher risk of developing islet autoantibodies and diabetes than the risk in children from the general population without a family history of the disease (GP children) (5–7). Enrichment of type 1 diabetes-susceptibility genotypes of HLA and other genes is likely to contribute to the inflated risk in FDR children. Understanding the genetic differences

¹Institute of Diabetes Research, Helmholtz Zentrum München (German Research Center for Environmental Health), Munich-Neuherberg, Germany

²Forschergruppe Diabetes, Klinikum rechts der Isar, Technical University Munich, Munich, Germany

³Pacific Northwest Research Institute, Seattle, WA

⁴Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL

⁵Forschergruppe Diabetes e.V., Helmholtz Zentrum München (German Research Center for Environmental Health), Munich-Neuherberg, Germany

⁶Department of Pediatrics, Turku University Hospital, and Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland

⁷Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden

⁸Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO

⁹Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA

¹⁰National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

¹¹Center for Public Health Genomics, University of Virginia, Charlottesville, VA

¹²DFG Center for Regenerative Therapies Dresden, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany

Corresponding authors: Anette-G. Ziegler, anette-g.ziegler@helmholtz-muenchen.de, and Ezio Bonifacio, ezio.bonifacio@tu-dresden.de

Received 16 August 2018 and accepted 4 January 2019

Clinical trial reg. no. NCT00279318, clinicaltrials.gov

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db18-0882/-/DC1>.

*A list of members of the TEDDY Study Group can be found in Supplementary Data.

© 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

and their contributions to the divergent risks between GP and FDR children could provide paradigms to identify novel genetic and environmental factors that modify risk and to identify GP children whose a priori risk of developing type 1 diabetes is similar to that of FDR children.

The Environmental Determinants of Diabetes in the Young (TEDDY) study has screened >400,000 newborns to identify and recruit >8,000 with high-risk HLA genotypes into a follow-up cohort that monitors the development of islet autoantibodies and diabetes (8,9). This cohort includes FDR and GP children, providing a rare opportunity to examine the excess risk of developing islet autoantibodies and diabetes in affected families. The children in the TEDDY study have been extensively genotyped (4). This allowed us to calculate genetic risk scores representing cumulative genetic susceptibility (10–12) and has enabled us to investigate which genes, beyond the known susceptibility regions, may contribute to risk. Here, we address whether the increased risk in FDR children is accounted for by enrichment of genetic susceptibility in TEDDY children with the highest-risk HLA genotypes (*DR3/DR4-DQ8* heterozygotes and *DR4-DQ8/DR4-DQ8* homozygotes). Using this approach, we could show enrichment of genetic susceptibility for multiple known risk genes and a novel risk gene. Matching FDR and GP children for genetic risk abrogated the excess risk in FDR children in the highest genetic risk stratum but not in the lower genetic risk strata. These findings provide evidence that additional factors preferentially contribute to type 1 diabetes risk in children without a full complement of genetic susceptibility.

RESEARCH DESIGN AND METHODS

The TEDDY study screened 424,788 newborns for type 1 diabetes-associated HLA genotypes between 2004 and 2010, of whom 8,676 children were enrolled and followed in six centers located in the U.S., Finland, Germany, and Sweden (Supplementary Fig. 1). Detailed information on the study design, eligibility, and methods has previously been published (3,8,9). Here, we used data as of 30 June 2017. Written informed consent was obtained for all participants from a parent or primary caretaker, separately, for genetic screening and for participation in prospective follow-up. The study was approved by local institutional review boards and is monitored by the External Evaluation Committee formed by the National Institutes of Health.

The datasets generated and analyzed during the current study are available in the National Institute of Diabetes and Digestive and Kidney Diseases Central Repository at www.niddkrepository.org/studies/teddy. TEDDY ImmunoChip SNP (single nucleotide polymorphism) data that support the findings of this study have been deposited in the National Center for Biotechnology Information Database of Genotypes and Phenotypes (dbGaP) with the primary accession code phs001037.v1.p1.

Genotyping and Genetic Risk Score

The HLA genotypes were confirmed by the central HLA Laboratory at Roche Molecular Systems (Oakland, CA) for enrolled subjects. The present report includes 4,572 TEDDY children with the *DR3-DQA1*05:01-DQB1*02:01/DR4-DQA1*03:0X-DQB1*03:02* genotype (HLA *DR3/DR4-DQ8*) or the *DR4-DQA1*03:0X-DQB1*03:02/DR4-DQA1*03:0X-DQB1*03:02* genotype (HLA *DR4-DQ8/DR4-DQ8*), if at least one sample was obtained after birth. SNP analysis was performed using the Illumina ImmunoChip (13). The genetic risk score was calculated from 40 SNPs similar to the previously described merged genetic score (12), except the value of the HLA *DR-DQ* genotype (3.98 for *DR3/DR4-DQ8* or 3.15 for *DR4-DQ8/DR4-DQ8*) was not included in the score.

TEDDY Study Outcomes

Blood samples were obtained every 3 months until age 4 years and biannually thereafter for the analysis of islet autoantibodies (insulin autoantibodies [IAA], GAD autoantibodies [GADA], and insulinoma antigen-2 autoantibodies). All radiobinding assays were performed as previously described (13,14). A positive outcome was defined as positive in both reference laboratories on two or more consecutive visits. The date of seroconversion (time to first autoantibody) was defined as the date of drawing the first of the two consecutive positive samples. The presence of multiple islet autoantibodies was defined as the presence of at least two islet autoantibodies. Diabetes was diagnosed according to American Diabetes Association criteria.

Statistics

The risks of developing one or more islet autoantibodies, multiple autoantibodies, and diabetes in FDR and GP children were assessed using Kaplan-Meier plots, and groups were compared using the log-rank test. Hazard ratios (HRs) were computed using Cox proportional hazards model. Genotype frequencies between GP and FDR children were compared using χ^2 tests with Bonferroni correction for multiple testing. All analyses were carried out with R 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria), using the GWASTools, haplo.stats, qqman, and survminer packages.

RESULTS

Risk of Developing Islet Autoantibodies and Diabetes According to HLA Genotype and First-degree Relative Status

Of the TEDDY children with at least one follow-up sample ($n = 7,894$), 3,035 (38.4%) had the HLA *DR3/DR4-DQ8* genotype and 1,537 (19.5%) had the HLA *DR4-DQ8/DR4-DQ8* genotype. Of these 4,572 children, 423 (9.3%) were FDR children and 4,149 were GP children (Table 1 and Supplementary Fig. 1). One or more islet autoantibodies developed in 500 (10.9%) children, of whom 324 (7.1%) had multiple islet autoantibodies. Diabetes was diagnosed in 192 (4.2%) children.

Table 1—Study characteristics by first-degree relative status

Variable	FDR children (n = 423)	GP children (n = 4,149)
Males	200 (47.3)	2,082 (50.2)
HLA genotype		
<i>DR3/4-DQ8</i>	280 (66.2)	2,755 (66.4)
<i>DR4-DQ8/DR4-DQ8</i>	143 (33.8)	1,394 (33.6)
Country		
U.S.	194 (45.9)	1,750 (42.2)
Finland	51 (12.1)	792 (19.1)
Germany	92 (21.7)	209 (5.0)
Sweden	86 (20.3)	1,398 (33.7)
First-degree relative with T1D		
None	0 (0.0)	4,149 (100.0)
Mother	146 (34.5)	0 (0.0)
Father	180 (42.6)	0 (0.0)
Sibling	79 (18.7)	0 (0.0)
Multiplex	18 (4.3)	0 (0.0)
Outcome events		
One or more islet autoantibodies	85 (20.1)	415 (10.0)
Multiple islet autoantibodies	69 (16.3)	255 (6.1)
First-appearing IAA	51 (12.1)	227 (5.5)
First-appearing GADA	46 (10.9)	250 (6.0)
Diabetes	47 (11.1)	145 (3.5)
Genetic risk score available	408 (96.5)	4,006 (96.6)
Data are n (%).		

Matching for HLA *DR-DQ* provided an estimate of the excess risk of developing islet autoantibodies or diabetes in FDR children that was due to factors other than enrichment for these genotypes (Fig. 1). Matching for HLA genotypes was sufficient to reduce the >10-fold excess risk usually observed in children from affected families to <3-fold. The cumulative risk by 6 years of age in HLA *DR3/DR4-DQ8* FDR children was 20.5% (95% CI 15.4–25.4%) for one or more islet autoantibodies, 17.0% (12.1–21.5%) for multiple islet autoantibodies, and 6.8% (3.8–9.7%) for diabetes compared with 10.0% (8.8–12.2%; $P < 0.0001$), 6.4% (5.4–7.4%; $P < 0.0001$), and 2.7% (2.0–3.3%; $P < 0.0001$), respectively, in GP children with these genotypes (Fig. 1A, C, and E). Similar differences were observed in the HLA *DR4-DQ8/DR4-DQ8* children (Fig. 1B, D, and F). A first-degree family history of type 1 diabetes was associated with an increased incidence of islet autoimmunity in the first 3 years of life in children with the high-risk HLA genotypes (Supplementary Fig. 2A). This was similar if the outcome was defined as the detection of IAA before other autoantibodies or GADA as the first islet autoantibodies (Supplementary Fig. 2B).

***DRB1*04* Allele Subtype Enrichment in Children From Affected Families**

The risk for type 1 diabetes is influenced by the HLA *DRB1*04* allele (15,16). We therefore searched for FDR enrichment of *DRB1*04* subtypes (Table 2). The high-risk *DRB1*04:01* allele was more frequent in the FDR children than in the GP children ($P < 0.0001$) for children with

either the *DR3/4-DQ8* ($P = 0.0067$) or *DR4-DQ8/DR4-DQ8* ($P = 0.0005$) genotypes. In contrast, the lower-risk *DRB1*04:04* ($P < 0.0001$) and *DRB1*04:07* ($P = 0.035$) alleles were less frequent in the FDR children than in GP children. There were no differences in the frequencies of the *DRB1*04:02* or the *DRB1*04:05* alleles between the FDR children and the GP children. The remaining *DRB1*04* alleles were infrequent in the study population and were not considered.

Genetic Risk Scores in FDR and GP Children

The additional non-HLA *DR-DQ* gene risk was expressed as a genetic risk score from 40 of the non-HLA *DR-DQ* SNPs (12). Genetic risk scores were higher in the FDR children (median 10.3 [interquartile range 9.7–11.0]) than in the GP children (10.1 [9.4–10.7]; $P < 0.0001$) (Fig. 2A). Enrichment of risk genotypes reached significance for six of the 40 SNPs (Supplementary Table 1). Similar genetic risk scores were observed in the multiple islet autoantibody-positive FDR children (10.4 [10.0–11.3]) and GP children (10.5 [10.0–11.1]; $P = 0.97$) (Fig. 2B).

Additional Genes With Allele Enrichment in FDR Children

HLA *DR-DQ* susceptible genotypes have additional variants in genes that are in linkage disequilibrium (LD) with HLA *DR-DQ* (17). We reasoned that the frequencies of susceptibility genotypes of such genes may be increased in the FDR children and could account for some of the excess risk in these children. With the rare opportunity to compare a large number of GP and FDR children matched for HLA *DR-DQ* genotype in the TEDDY study, we examined 6,097 SNPs with minor allele frequencies >5% on the short arm of chromosome 6, containing the HLA genes (6p21.32). SNPs *rs3763305* ($P = 7.27 \times 10^{-7}$) and *rs3817964* ($P = 8.26 \times 10^{-7}$) were enriched in the FDR children (Supplementary Fig. 3A). Both SNPs are intronic variants of *BTNL2* and are in complete LD ($r^2 = 1$). The *BTNL2* gene is located close to the HLA *DRA/HLA DRB5/HLA DRB1* cluster and HLA *DQB1*. Extension of the analysis to all 111,069 ImmunoChip SNPs that passed quality control filters identified *rs7735139* (intronic SNP in *ITGA1* [integrin subunit α 1, 5q11.2]) with allelic enrichment in the FDR children ($P = 4.34 \times 10^{-8}$) (Supplementary Fig. 3B).

Genetic Contribution to the Additional Risk for Islet Autoantibodies and Diabetes in FDR Children

Cox proportional hazards models were used to assess the development of one or more islet autoantibodies, multiple islet autoantibodies, and diabetes (Table 3). Model 1 examined the excess risk conferred by a first-degree family history of type 1 diabetes adjusted for HLA genotype (*DR3/4-DQ8* vs. *DR4-DQ8/DR4-DQ8*), sex, and country of origin. HRs in the FDR children were 2.12 (95% CI 1.65–2.72) for one or more islet autoantibodies, 2.77 (95% CI 2.09–3.68) for multiple




Figure 1—Cumulative risks of islet autoantibodies and diabetes. Kaplan-Meier curves for the risk of one or more islet autoantibodies (A and B), multiple islet autoantibodies (C and D), and diabetes (E and F) in FDR children (red) and in GP children (blue), stratified into children with the HLA DR3/DR4-DQ8 (A, C, and E) or HLA DR4-DQ8/DR4-DQ8 (B, D, and F) genotypes. Shaded areas represent the 95% CI. Numbers represent children at risk. P values were calculated using log-rank tests.

Table 2—Allelic enrichment of *DRB1*04* subtypes in FDR children

DR4 subtype	FDR children (alleles, n = 535)	GP children (alleles, n = 5,415)	P*
<i>DRB1*04:01</i>	329 (60.15)	2,788 (51.49)	<0.0001
<i>DRB1*04:02</i>	33 (6.03)	291 (5.37)	0.42
<i>DRB1*04:04</i>	137 (25.05)	1,928 (35.60)	<0.0001
<i>DRB1*04:05</i>	23 (4.20)	226 (4.17)	0.91
<i>DRB1*04:06</i>	1 (0.18)	1 (0.02)	0.17
<i>DRB1*04:07</i>	7 (1.28)	153 (2.83)	0.035
<i>DRB1*04:08</i>	4 (0.73)	25 (0.46)	0.33
<i>DRB1*04:10</i>	0 (0.00)	1 (0.02)	1
<i>DRB1*04:11</i>	1 (0.18)	1 (0.02)	0.17
<i>DRB1*04:13</i>	0 (0.00)	1 (0.02)	1

Data are n (%). Each *DRB1*04* allele was counted separately (once for children with the *DR3/DR4-DQ8* genotype and twice for children with the *DR4-DQ8/DR4-DQ8* genotype). *DRB1*04* subtype information was missing in 77 *DR3/DR4-DQ8* and 35 *DR4-DQ8/DR4-DQ8* children. Children with the nonrisk *DRB1*04:03* allele were excluded a priori from the TEDDY study unless they had a first-degree relative with type 1 diabetes, and the 12 occurrences of this allele in FDR children were therefore not considered. *P values were calculated using Fisher test.

islet autoantibodies, and 3.69 (95% CI 2.60–5.23) for diabetes.

For determination of whether the genetic factors that were enriched in FDR children contributed to the excess risk in FDR children, model 2 added the non-HLA *DR-DQ* genetic risk score, *DRB1*04* subtype (enriched, *DR3/DRB1*04:01* and *DRB1*04:01/DR*04:xx*, where **04:xx* is neither **04:04* nor **04:07*, vs. nonenriched, other genotypes), the *BTNL2* SNP rs3763305 (enriched, GG, vs. nonenriched, GA/AA genotypes), and the *ITGA1* SNP rs7735139 (enriched, GG, vs. nonenriched, GA/AA genotypes). HRs for FDR children were reduced to 1.82 (95% CI 1.42–2.35) for one or more islet autoantibodies, 2.26 (95% CI 1.70–3.02) for multiple islet autoantibodies, and 2.92

(95% CI 2.05–4.16) for diabetes. The enriched *DRB1*04:01* subtype (HR 1.48 [95% CI 1.08–2.01]; P = 0.014) and the non-HLA *DR-DQ* genetic risk score (HR 1.66 [95% CI 1.47–1.88]; P < 0.0001) contributed to the risk of multiple islet autoantibodies. Similar HRs for these variables were also observed for the risk of one or more islet autoantibodies and diabetes, some of which reached significance. The *BTNL2* SNP rs3763305 GG genotype conferred additional risk for diabetes (HR 1.80 [95% CI 1.11–2.93]; P = 0.017) (Table 3), and this additional risk was also observed when the analysis was restricted to children with an HLA *DR3/4-DQ8* genotype (HR 1.92 [95% CI 1.11–3.35]; P = 0.021) (Supplementary Table 2). The *ITGA1* SNP was not associated with risk.

Association Between *DRB1*04* Subtypes and Islet Autoantibodies or Diabetes

To further assess whether the *DRB1*04:01* allele was associated with increased risk compared with the other *DRB1*04* alleles in the TEDDY children, we removed the confounder of family history and performed a Kaplan-Meier analysis in the GP children. Among the 1,876 children with the *DRB1*04:01* allele, the cumulative risks at 6 years old were 11.4% (95% CI 9.8–12.9%) for one or more islet autoantibodies, 7.7% (6.3–9.0%) for multiple islet autoantibodies, and 2.9% (2.1–3.6%) for diabetes compared with 6.8% (5.7–8.0%; P < 0.0001), 4.0% (3.1–4.9%; P < 0.0001), and 1.4% (0.9–1.9%; P < 0.0001), respectively, among 2,176 children without *DRB1*04:01* (Supplementary Fig. 4A, C, and E). These differences remained when the analysis was limited to GP children with the HLA *DR3/DR4-DQ8* genotype (Supplementary Fig. 4B, D, and F).

Association Between *BTNL2* Genotypes and Islet Autoantibodies or Diabetes

Variants in the *BTNL2* gene have not been implicated as independent genetic risk factors for type 1 diabetes previously, likely due to the extensive LD in the MHC region




Figure 2—A: Distribution of non-HLA *DR-DQ* genetic risk scores in all 4,414 *DR3/DR4-DQ8* or *DR4-DQ8/DR4-DQ8* children stratified into FDR children (red) and GP children (blue). **B:** Distribution of non-HLA *DR-DQ* genetic risk scores in 317 *DR3/DR4-DQ8* or *DR4-DQ8/DR4-DQ8* children who developed multiple islet autoantibodies. P values were calculated using the two-sided Mann-Whitney U test.

Table 3—Cox proportional hazards models for developing islet autoantibodies and diabetes in FDR children compared with GP children (reference)

	One or more islet autoantibodies						Multiple islet autoantibodies						Diabetes					
	Model 1*		Model 2*		Model 1*		Model 2*		Model 1*		Model 2*		Model 1*		Model 2*			
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P		
FDR child	2.12 (1.65–2.72)	<0.0001	1.82 (1.42–2.35)	<0.0001	2.77 (2.09–3.68)	<0.0001	2.26 (1.70–3.02)	<0.0001	3.69 (2.60–5.23)	<0.0001	2.92 (2.05–4.16)	<0.0001	1.38 (0.93–2.04)	0.1052	1.67 (1.42–1.96)	<0.0001		
<i>DRB1*04:01/x†</i>			1.42 (1.10–1.83)	0.0075			1.48 (1.08–2.01)	0.014										
Genetic risk score‡			1.48 (1.34–1.64)	<0.0001			1.66 (1.47–1.88)	<0.0001										
<i>BTNL2</i> rs3763305			1.05 (0.79–1.40)	0.73			1.39 (0.96–2.00)	0.080										
GG§			1.18 (0.86–1.63)	0.30			1.06 (0.70–1.60)	0.77										
<i>ITGA1</i> rs7735139 GG§																		

*Model 1 and 2 are adjusted for sex, country (reference: U.S.), and HLA genotype (reference: *DR4-DQ8/DR4-DQ8*). †Reference: *DRB1* without 04:01 or 04:01/04:04 and 04:01/04:07. ‡Per unit increase. §Reference: GAA genotype.

and inadequate sample size. The *BTNL2* rs3763305 GG genotype distribution was increased in children who developed one or more islet autoantibodies ($P < 0.0001$), multiple islet autoantibodies ($P < 0.0001$), or diabetes ($P < 0.0001$) compared with children who remained islet autoantibody negative. These associations were observed separately for children with HLA *DR3/4-DQ8* or *DR4-DQ8/DR4-DQ8* (Table 4). The association between the *BTNL2* rs3763305 GG genotype and type 1 diabetes was also validated in the Type 1 Diabetes Genetics Consortium (T1DGC), using a nested case-control comparison after stratification for HLA *DR3/4-DQ8* (Supplementary Table 3).

The ImmunoChip contained 88 SNPs that were genotyped within *BTNL2*, including 34 that passed all quality-control metrics. The ImmunoChip genotypes were used to define haplotypes using the R package haplo.stats (Supplementary Table 4). The risk associated with the four most frequent *BTNL2* genotypes among children with *DR3/DR4-DQ8* and the four most frequent genotypes among children with *DR4-DQ8/DR4-DQ8* was stratified by the presence of haplotype 28, which uniquely contained an A allele at *BTNL2* rs3763305 and a T allele at *BTNL2* rs3817964 (Supplementary Fig. 5).

BTNL2 lies close to the HLA *DRB5/HLA DRB6/HLA DRB1* protein-coding genes in a region of high LD. HLA *DR3* was in nearly complete LD with the rs3763305 G allele: the *BTNL2* rs3763305 GG genotype was identified in 1,608 (99.3%) of 1,619 children who had the HLA *DR3/DR3* genotype (Supplementary Table 5). We next examined the second *BTNL2* rs3763305 allele in children with *DR3/DR4-DQ8*. The *BTNL2* rs3763305 G allele was in nearly complete LD with *DRB1*04:01* (allele frequency 99.5%), *DRB1*04:02* (99.4%), and *DRB1*04:05* (100.0%), whereas the *BTNL2* rs3763305 A allele was associated with *DRB1*0404* (39.2%) and *DRB1*0407* (34.4%) ($P < 0.0001$). These associations were confirmed in a separate cohort of 149 children with type 1 diabetes and the *DR3/DR4-DQ8* genotype from Bavaria, Germany (Supplementary Table 6). The *BTNL2* rs3763305 A allele was also observed together with the protective HLA *DRB1*04:03* allele in five (56%) of nine informative genotypes and with the protective HLA *DRB1*13:01* allele in 10 (25%) of 40 informative genotypes but not with other HLA *DRB1* alleles in the German cohort (data not shown).

The *DRB1*04:04* allele together with either the *BTNL2* rs3763305 G or the *BTNL2* rs3763305 A allele was relatively frequent in the TEDDY children and, therefore, provided an opportunity to determine whether the *BTNL2* gene conferred an independent risk to the HLA *DR4* subtype. Risks associated with *BTNL2* genotypes were examined in children with the *DR3/DRB1*04:04-DQ8* or *DRB1*04:04-DQ8/DRB1*04:04-DQ8* genotypes. The cumulative risks at 6 years of age in children with the *BTNL2* rs3763305 GG genotype were 9.8% (95% CI 5.6–13.8%) for one or more islet autoantibodies, 6.3%

Table 4—*BTNL2* SNP genotype frequencies in relation to the development of islet autoantibodies and diabetes among TEDDY children with HLA *DR3/DR4-DQ8* or *DR4-DQ8/DR4-DQ8* and available genotype information

	Islet autoantibody negative	One or more islet autoantibodies	Multiple islet autoantibodies	Diabetes
HLA <i>DR3/4-DQ8</i> (<i>n</i> = 3,024), <i>BTNL2</i> SNP rs3763305				
GG	1,839 (69.1)	272 (75.3)	190 (79.8)	120 (82.8)
GA	823 (30.9)	89 (24.7)	48 (20.2)	25 (17.2)
AA	1 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>P</i> *		0.030	0.0007	0.0007
HLA <i>DR4-DQ8/DR4-DQ8</i> (<i>n</i> = 1,532), <i>BTNL2</i> SNP rs3763305				
GG	692 (49.7)	89 (64.0)	63 (73.3)	36 (76.6)
GA	571 (41.0)	44 (31.7)	21 (24.4)	10 (21.3)
AA	130 (9.3)	6 (4.3)	2 (2.3)	1 (2.1)
<i>P</i> *		0.0033	<0.0001	0.0010

Data are *n* (%). *Children who remained islet autoantibody negative were compared with children who developed one or more islet autoantibodies, multiple islet autoantibodies, and diabetes using Fisher test.

(2.9–9.6%) for multiple islet autoantibodies, and 3.7% (1.3–6.0%) for diabetes compared with 8.0% (6.2–9.8%; *P* = 0.46), 4.7% (3.3–6.2%; *P* = 0.096), and 1.6% (0.8–6.0%; *P* = 0.0048) in the children with the GA or AA genotypes (Fig. 3). Cox proportional hazards models adjusted for *DR3/DRB1*04:04-DQ8* or *DRB1*04:04-DQ8/DRB1*04:04-DQ8* genotype replicated the additional risk for diabetes conferred by the *BTNL2* rs3763305 GG genotype (*P* = 0.0086) (Supplementary Table 7).

The additional risk conferred by the *BTNL2* rs3763305 GG genotype may be due to a specific association with specific *DRB1*04:04* subtypes. We, therefore, examined the relationship between the *BTNL2* rs3763305 alleles and *DRB1*04:04* subtypes in the German cohort of patients who had been HLA genotyped by sequencing of HLA *DRB1* exon 2, which harbors variations in all 12 subtypes of *DRB1*04:04*. All subjects with *DRB1*04:04* had the *DRB1*04:04:01* allele regardless of whether the *BTNL2* rs3763305 was A or G, indicating that the *BTNL2* rs3763305 A allele does not appear to mark a subtype of *DRB1*04:04*.

Finally, we examined the effect of *BTNL2* knockdown on in vitro immune responses (Supplementary Fig. 6). Compared with nontargeting siRNA control treated dendritic cells, *BTNL2*-targeted siRNA-treated dendritic cells had increased naïve alloreactive CD4⁺ T-cell activation (*P* = 0.031) but not memory antigen-specific CD4⁺ T-cell activation (*P* = 0.43).

Risk Excess in FDR Children After Stratification by Genetic Risk

We asked whether the observed enrichment of type 1 diabetes genetic susceptibility in the FDR children could account for their excess risk. Four risk strata were defined by HLA *DRB1*04* subtype and genetic risk score. With these strata, we could discriminate the risk of developing islet autoantibodies and T1D in

the GP children (Fig. 4A, C, and E). A similar stratification in the GP children was observed if the strata were defined by the children's *BTNL2* genotype and genetic risk score (Supplementary Fig. 7). In contrast to the GP children, a discrimination of risk in the FDR children was only achieved in the lowest risk stratum (Fig. 4B, D, and F). Comparing FDR children and GP children showed complete convergence of the risks of developing islet autoantibodies and diabetes in the highest-risk stratum and divergence of risk in the lower-risk strata (Supplementary Table 8). The fold difference in risk for multiple islet autoantibodies between the FDR and GP children was 1.1 in the highest-risk stratum (14.3% vs. 12.7%), 1.9 in the second risk stratum (17% vs. 9%), 3.3 in the third risk stratum (14.8% vs. 4.5%), and 5.8 in the lowest-risk stratum (9.2% vs. 1.6%).

Risk in FDR Children Is Modified by Maternal, Paternal, and Sibling Type 1 Diabetes

Risk divergence at lower genetic susceptibility strata implied that additional factors that influence risk may act differently depending on the a priori genetic susceptibility. One factor that is known to affect risk in FDR children is maternal type 1 diabetes (18). The HRs for one or more islet autoantibodies (2.37 [95% CI 1.71–3.28]), multiple islet autoantibodies (2.89 [95% CI 2.00–4.17]), and diabetes (3.06 [95% CI 1.89–4.94]), were increased compared with GP children if the first-degree relative index case was a father. The HRs were also increased if the first-degree relative was a sibling. By contrast, if the first-degree relative index case was the mother, the HR was not increased for one or more islet autoantibodies (0.85 [0.50–1.44]), multiple islet autoantibodies (0.97 [95% CI 0.52–1.7]), and diabetes (1.39 [95% CI 0.67–2.87]) (Supplementary Table 9). This relative protection conferred by maternal type 1 diabetes versus paternal or sibling type 1 diabetes was observed in the higher risk strata (Supplementary Fig. 8).




Figure 3—The modification of risk by the *BTNL2* SNP rs3763305 on the development of one or more islet autoantibodies (A), multiple islet autoantibodies (B), and diabetes (C) in children with the *DR3/DRB1*04:04-DQ8* or *DRB1*04:04-DQ8/DRB1*04:04-DQ8* genotypes. Risks are shown for the GG genotype versus the GA or AA genotypes at rs3763305. *P* values were calculated using log-rank tests.

DISCUSSION

We found that the excess risk for islet autoantibodies and diabetes in FDR children could be abrogated by accounting for an increased load of type 1 diabetes susceptibility alleles at multiple loci, including a novel susceptibility region marked by SNPs within the *BTNL2* gene. The risk converged when children were matched at the highest genetic susceptibility and became increasingly divergent as genetic susceptibility was attenuated. These data suggest that additional factors shared within families may modify type 1 diabetes risk heterogeneously and are dependent upon a priori genetic susceptibility.

The study was performed in a large number of FDR and GP children of mainly European descent who were matched for the two highest-risk HLA class II genotypes. This unique cohort allowed us to assess the contributions of other genetic factors. After selection by HLA genotype, the excess risk for islet autoantibodies and diabetes was approximately two- to threefold higher in FDR children, which is markedly less than the >10-fold excess observed without HLA selection. Enrichment of genetic susceptibility was observed for HLA *DR4* subtypes and by an increased genetic risk score for non-HLA loci. The addition of these genetic markers further reduced the excess risk in FDR children, but the adjusted HRs remained >2 for the development of multiple islet autoantibodies or diabetes. Remarkably, this excess risk was heterogeneous and depended on the a priori genetic susceptibility. A limitation of our study is that we could not examine children with other HLA genotypes and, therefore, cannot assess whether the divergence continues in children with HLA genotypes associated with moderate or low risk. Although TEDDY is a unique study with unprecedented numbers of FDR and GP children for comparisons, the findings require further validation, especially in different ethnic populations.

The excess risk that remained unaccounted for by susceptibility genes in families is likely due to further genetic enrichment, including rare variants that may be

more frequent in familial cases, or other factors, such as a shared environment. The study provided the opportunity to search for additional genetic factors that may contribute to risk by exploring genes with allelic enrichment in FDR children. A limitation of this approach is that, despite the size of the TEDDY study, there was relatively little power to find these genes across the whole genome, particularly for genes with low minor allele frequencies.

We were successful in finding an enrichment of alleles for two additional genes. One of the genes with allelic enrichment in the FDR children, *BTNL2*, lies within the HLA class II region. SNPs within *BTNL2* were previously shown to be associated with other HLA DR-linked diseases, but in almost all cases, including type 1 diabetes, the risk was attributed to LD with HLA DR (19). Our study, which included >3,000 children with the HLA *DR3/DR4-DQ8* genotype and >1,500 with the *DR4-DQ8/DR4-DQ8* genotype, had sufficient power to adequately test the independent contribution of *BTNL2*. The G allele of the SNP rs3763305 increased the risk for type 1 diabetes, with an HR of ~1.7 in these HLA-selected children. Although our analyses also controlled for the HLA *DRB1*04* subtype, we cannot exclude the possibility that the *BTNL2* SNP marks HLA *DR4* extended haplotypes. However, there was an association between the nonsusceptible *BTNL2* allele and *DRB1*04* subtypes that are protective or confer relatively low risk. It is, therefore, equally possible that some of the associations between *DRB1*04* subtype and type 1 diabetes risk are due to variation in *BTNL2* rather than or in addition to HLA DR. *BTNL2* is a negative regulator of immunity that is expressed on antigen-presenting cells and affects the generation, proliferation, and function of regulatory T cells (20–22) and, as shown here, activation of naïve CD4⁺ T cells. It was demonstrated that *BTNL2* SNPs confer risk for sarcoidosis (23), a T cell–related inflammatory disease, independently of HLA DR (24), and influence antibody responses to dietary antigens (25). A relationship between the minor allele of the *BTNL2* rs3763305 genotype and *BTNL2* transcriptomic expression has been




Figure 4—Risk of developing islet autoantibodies and diabetes in FDR children (B, D, and F) and in GP children (A, B, and C) according to genetic susceptibility strata based on HLA *DRB1*04* subtype and genetic risk score. Risks are shown for the development of one or more islet autoantibodies (A and B), multiple islet autoantibodies (C and D), and diabetes (E and F). All of the children had the *DR3/DR4-DQ8* or *DR4-DQ8/DR4-DQ8* genotype. Genetic susceptibility strata were defined as 1) high-risk *DRB1*04* subtype (*DR3/DRB1*04:01* or *DRB1*04:01-DQ8/DR4* without 04:04 or 04:07) and GRS in the upper quartile (gray), 2) high-risk *DRB1*04* subtype and GRS in the second quartile or lower-risk *DRB1*04* subtype and GRS in the upper quartile (pink), 3) high-risk *DRB1*04* subtype and GRS in the lower 50th centile or lower-risk *DRB1*04* subtype and GRS in the second quartile (light blue), and 4) lower-risk *DRB1*04* subtype and GRS in the lower 50th centile (green). The strata appear in this order from top to bottom in the risk tables. P values were calculated across all strata using log-rank tests.

reported (26). Further studies are required to determine whether there are functional differences between *BTNL2* genotypes that may be relevant to type 1 diabetes susceptibility.

The remaining increased risk for islet autoimmunity and type 1 diabetes in FDR children after accounting for genetic load implies that other factors, which are shared or enriched within affected families, contribute to the child's risk. It is known that a family history of type 1 diabetes is associated with changes in parental practices in an effort to reduce the risk in their unaffected children. It is likely that such practices are more frequent in the children of affected families, and it seems possible that some of these practices may be associated with increased risk. It is also possible that family members more often share infections or diet that increase the risk for islet autoimmunity. One enriched factor in the FDR children is maternal type 1 diabetes, which is known to offer relative protection (18). Indeed, unlike children whose father or sibling had type 1 diabetes, there was no excess risk in children whose mother had type 1 diabetes compared with GP children in the Cox proportional hazards model. The relative protection conferred by maternal compared with paternal type 1 diabetes was pronounced in the higher genetic susceptibility strata, suggesting that maternal type 1 diabetes harbors a dominantly protective environment in the presence of enriched genetic susceptibility. These data also suggest that the shared environment of siblings and fathers with type 1 diabetes may be a source from which to identify environmental risk factors.

In summary, we have shown that the increased risk of developing islet autoimmunity in FDR children is largely due to an excess load of genetic susceptibility, we identified a potential novel gene that confers risk for islet autoimmunity, and we have shown that accounting for the excess genetic susceptibility leads to convergence in high-risk strata and divergence in lower-risk strata for the risk of developing islet autoantibodies and diabetes between FDR children and GP children. These findings stress that environmental risk factors of disease will likely exert different effects in a gene-dependent manner and that searching for these factors may require genetic stratification. Of practical relevance, the study showed that it is possible to identify GP children whose risk for islet autoantibodies and type 1 diabetes is as high as that in the highest-risk FDR children.

Acknowledgments. Part of this work has been performed as PhD thesis work (M.H.) at the Technical University of Munich

Funding. The TEDDY study is funded by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, National Institutes of Health (NIH) (U01-DK-63829, U01-DK-63861, U01-DK-63821, U01-DK-63865, U01-DK-63863, U01-DK-63836, U01-DK-63790, UC4-DK-63829, UC4-DK-63861, UC4-DK-63821, UC4-DK-63865, UC4-DK-63863, UC4-DK-63836, UC4-DK-95300, UC4-DK-100238, UC4-DK-106955, and HHSN267200700014C), and by the

JDRF and Centers for Disease Control and Prevention. This work was supported in part by the NIH/National Center for Advancing Translational Sciences Clinical and Translational Science Award to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR001082).

The funders had no impact on the study design, implementation, or analysis or interpretation of data.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. M.H., W.A.H., J.P.K., J.K., C.W., J.T., Å.L., M.J.R., J.-X.S., C.C.R., S.O.-G., S.S.R., and A.-G.Z. contributed to data collection. M.H., A.B., K.V., J.K., C.C.R., E.B., and A.-G.Z. performed the statistical analyses. M.H., A.B., W.A.H., J.P.K., K.V., J.K., C.W., J.T., Å.L., M.J.R., A.K.S., J.-X.S., B.A., S.S.R., E.B., and A.-G.Z. contributed to the interpretation of data. M.H., A.B., C.W., E.B., and A.-G.Z. drafted the manuscript. M.H., A.B., W.A.H., J.P.K., K.V., J.K., C.W., J.T., Å.L., M.J.R., A.K.S., J.-X.S., B.A., C.C.R., S.O.-G., S.S.R., E.B., and A.-G.Z. critically reviewed the manuscript for important intellectual content. E.B. and A.-G.Z. designed the study. A.-G.Z. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in poster form at the Immunology of Diabetes Society Congress 2018 Poster Session B, London, England, 26 October 2018.

References

- Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA* 2013;309:2473–2479
- Schenker M, Hummel M, Ferber K, et al. Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with type 1 diabetes: the German BABYDIAB study. *Diabetologia* 1999;42:671–677
- Hagopian WA, Erlich H, Lernmark A, et al.; TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. *Pediatr Diabetes* 2011;12:733–743
- Törn C, Hadley D, Lee HS, et al.; TEDDY Study Group. Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study. *Diabetes* 2015;64:1818–1829
- Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. *Immunity* 2010;32:468–478
- Krischer JP, Lynch KF, Lernmark Å, et al.; TEDDY Study Group. Genetic and Environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the TEDDY study. *Diabetes Care* 2017;40:1194–1202
- Raab J, Haupt F, Scholz M, et al.; F1da Study Group. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the F1da study. *BMJ Open* 2016;6:e011144
- TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. *Pediatr Diabetes* 2007;8:286–298
- TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. *Ann N Y Acad Sci* 2008;1150:1–13
- Winkler C, Krumsiek J, Buettner F, et al. Feature ranking of type 1 diabetes susceptibility genes improves prediction of type 1 diabetes. *Diabetologia* 2014;57:2521–2529
- Oram RA, Patel K, Hill A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. *Diabetes Care* 2016;39:337–344
- Bonifacio E, Beyerlein A, Hippich M, et al.; TEDDY Study Group. Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children. *PLoS Med* 2018;15:e1002548
- Krischer JP, Lynch KF, Schatz DA, et al.; TEDDY Study Group. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. *Diabetologia* 2015;58:980–987

14. Bonifacio E, Yu L, Williams AK, et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. *J Clin Endocrinol Metab* 2010; 95:3360–3367
15. Erlich H, Valdes AM, Noble J, et al.; Type 1 Diabetes Genetics Consortium. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes* 2008; 57:1084–1092
16. Reijonen H, Nejentsev S, Tuokko J, et al.; The Childhood Diabetes in Finland Study Group. HLA-DR4 subtype and -B alleles in DQB1*0302-positive haplotypes associated with IDDM. *Eur J Immunogenet* 1997;24:357–363
17. Nejentsev S, Howson JM, Walker NM, et al.; Wellcome Trust Case Control Consortium. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. *Nature* 2007;450:887–892
18. Bonifacio E, Pflüger M, Marienfeld S, Winkler C, Hummel M, Ziegler AG. Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA(1c). *Diabetologia* 2008;51:1245–1252
19. Orozco G, Eerligh P, Sánchez E, et al. Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. *Hum Immunol* 2005;66:1235–1241
20. Arnett HA, Escobar SS, Viney JL. Regulation of costimulation in the era of butyrophilins. *Cytokine* 2009;46:370–375
21. Swanson RM, Gavin MA, Escobar SS, et al. Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells. *J Immunol* 2013;190:2027–2035
22. Sinisalo J, Vlachopoulou E, Marchesani M, et al. Novel 6p21.3 risk haplotype predisposes to acute coronary syndrome. *Circ Cardiovasc Genet* 2016;9: 55–63
23. Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. *Nat Genet* 2005;37:357–364
24. Wolin A, Lahtela EL, Anttila V, et al. SNP variants in major histocompatibility complex are associated with sarcoidosis susceptibility—a joint analysis in four European populations. *Front Immunol* 2017;8:422
25. Rubicz R, Yolken R, Alaedini A, et al. Genome-wide genetic and transcriptomic investigation of variation in antibody response to dietary antigens. *Genet Epidemiol* 2014;38:439–446
26. Fehrmann RS, Jansen RC, Veldink JH, et al. Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. *PLoS Genet* 2011;7: e1002197

SUPPLEMENTARY DATA

Genetic contribution to the divergence in type 1 diabetes risk between children from the general population and children from affected families

Markus Hippich,¹ Andreas Beyerlein,^{1,2} William A. Hagopian,³ Jeffrey P. Krischer,⁴ Kendra Vehik,⁴ Jan Knoop,¹ Christiane Winker,^{1,5} Jorma Toppari,⁶ Åke Lernmark,⁷ Marian J. Rewers,⁸ Andrea K. Steck,⁸ Jin-Xiong She,⁹ Beena Akolkar,¹⁰ Catherine C. Robertson,¹¹ Suna Onengut-Gumuscu,¹¹ Stephen S. Rich,¹¹ Ezio Bonifacio,^{5,12} Anette-G. Ziegler,^{1,2,12} and the TEDDY Study Group

Content

Supplementary Figures

Supplementary Figure 1. Flow chart of study population

Supplementary Figure 2. Incidence islet autoantibodies in FDR children compared with GP children by the age of seroconversion

Supplementary Figure 3. Manhattan plot of allele enrichment in FDR children

Supplementary Figure 4. Risk of developing islet autoantibodies and diabetes in GP children with respect to HLA *DRB1*04:01* alleles

Supplementary Figure 5. Kaplan–Meier curves for the risk of islet autoantibodies and diabetes in children stratified according to *BTNL2* haplotypes

Supplementary Figure 6. Effect of *BTNL2* knockdown in monocyte-derived dendritic cells on CD4+ T cell activation

Supplementary Figure 7. Risk of developing islet autoantibodies and diabetes in FDR children and in GP children according to genetic susceptibility strata based on *BTNL2* SNP rs3763305 and genetic risk score (GRS).

Supplementary Figure 8. Risk of developing islet autoantibodies and diabetes in children with a mother with type 1 diabetes compared with children with a father or sibling with type 1 diabetes.

Supplementary Tables

Supplementary Table 1. Genotype frequencies for SNPs used in the T1D genetic risk score

Supplementary Table 2. Cox proportional hazards models for the development of islet autoantibodies and diabetes in TEDDY children with the HLA *DR3/4-DQ8* genotype

Supplementary Table 3. Genotype frequencies of *BTNL2* SNP rs3765503 in validation cohort

Supplementary Table 4. Haplotypes of 34 SNPs in *BTNL2*

Supplementary Table 5. Relationship between *BTNL2* SNP rs3765503 genotypes and HLA *DR3* and *DRB1*04* subtype alleles in TEDDY children with the HLA *DR3/DR4-DQ8* genotype

Supplementary Table 6. Relationship between *BTNL2* rs3763305 genotypes with HLA *DRB1*04* subtype alleles in patients from the Bavarian diabetes registry DiMelli

Supplementary Table 7. Cox proportional hazards models for developing islet autoantibodies and diabetes according to *BTNL2* rs3763305 genotype in children with the *DRB1*0404* allele

Supplementary Table 8. Cumulative risk of developing islet autoantibodies or diabetes by 6 years old in children stratified by genetic risk score and HLA *DRB1*04* subtype


Supplementary Table 9. Cox proportional hazards models for developing islet autoantibodies and diabetes in FDR children with respect to the affected family member.

Supplementary Acknowledgements

Supplementary References


SUPPLEMENTARY DATA

Supplementary Figure 1. Flow chart of study population



SUPPLEMENTARY DATA


Supplementary Figure 2. (A) Incidence of one or more islet autoantibodies among *DR3/4-DQ8* and *DR4-DQ8/DR4-DQ8* FDR children (red) compared with GP children (blue) by the age of seroconversion. (B) Incidence of first-appearing IAA (solid lines) and first-appearing GADA (broken lines) at seroconversion in *DR3/4-DQ8* and *DR4-DQ8/DR4-DQ8* FDR children (red) compared with GP children (blue) by the age of seroconversion.



SUPPLEMENTARY DATA


Supplementary Figure 3. Manhattan plot of allele enrichment in FDR children. SNPs were analyzed across the HLA region on chromosome 6 (A) and across all ImmunoChip data (B).

P -values were calculated using χ^2 tests. The thresholds for P -values after Bonferroni correction (8.2×10^{-6} and 4.5×10^{-7}) are indicated using solid lines.




SUPPLEMENTARY DATA

Supplementary Figure 4. Risk of developing one or more islet autoantibodies (A, B), multiple islet autoantibodies (C, D) and diabetes (E, F) in GP children with HLA *DR3/DR1*04:01-DQ8* or *DR1*04:01-DQ8/DR1*04:xx-DQ8*, where **04:xx* was any allele other than *DR1*04:04* or *DR1*04:07* (red) vs children without *DR1*04:01* (blue). The risks are also shown separately for GP children with HLA *DR3/DR4*04:01-DQ8* (B, D, F). *P*-values were calculated using log-rank tests.



SUPPLEMENTARY DATA


Supplementary Figure 5. Kaplan–Meier curves for the risk of one or more islet autoantibodies (A, B), multiple islet autoantibodies (C, D), and diabetes (E, F) in GP children stratified into children with the *HLA DR3/DR4-DQ8* (A, C, E) or *HLA DR4-DQ8/DR4-DQ8* (B, D, F) genotypes and according to *BTNL2* haplotypes. For both HLA genotypes, the 4 major *BTNL2* genotypes are shown. The genotypes that include haplotype 28, which is the only *BTNL2* haplotype that has the SNP rs3763305 A allele, are indicated as thick blue lines. Shaded areas represent the 95% CI. Numbers represent children at risk. P-values were calculated using log-rank tests.





SUPPLEMENTARY DATA

Supplementary Figure 6. Effect of *BTNL2* knockdown in monocyte-derived dendritic cells on CD4⁺ T cell activation. A. Activation of isolated CD4⁺ CD25⁻ T cells by allogeneic monocyte-derived dendritic cells transfected with non-targeting siRNA or *BTNL2* targeting siRNA in mixed lymphocyte cultures. CD71 expression, previously reported as a marker of allo-reactive T cell activation, was used to measure the activation of the CD4⁺ T cells. Dendritic cells were transfected as previously described (1). The upper panels are exemplary FACS plots for 42 hour cultures of CD4⁺ T cells only and in the presence of allo-reactive transfected dendritic cells. The lower graph indicates the mean frequency CD71⁺ CD45RA⁺ CD4⁺ T cells at the end of the 42 hour culture (4 replicates) after subtraction of the mean frequency of CD71⁺ CD45RA⁺ CD4⁺ T cells in quadruplicate cultures without dendritic cells. Each of three dendritic cell samples was tested against two different allogeneic CD4⁺ T cell preparation yielding 6 data sets. Activation was increased when CD4⁺ T cells were activated with dendritic cells transfected with *BTNL2*-targeting siRNA as compared to non-targeting siRNA ($p=0.031$, Wilcoxon matched pair sign test). B. Activation of isolated CD4⁺ CD25⁻ T cells by autologous monocyte-derived dendritic cells transfected with non-targeting siRNA or *BTNL2*-targeting siRNA in the presence of flu or tetanus toxoid antigen. CD69 expression was used to measure the activation of the CD4⁺ T cells. The upper panels are exemplary FACS plots for 42 hour cultures of CD4⁺ T cells plus dendritic cells in the presence and absence of flu antigen. The lower graph indicates the mean frequency CD69⁺ CD4⁺ T cells at the end of the 42 hour culture (triplicates) after subtraction of the mean frequency of CD69⁺ CD4⁺ T cells in triplicates cultures without antigen. Each of three dendritic cell samples was tested against flu and tetanus toxoid yielding 6 data sets. Activation was not different when CD4⁺ T cells were activated with dendritic cells transfected with *BTNL2*-targeting siRNA as compared to non-targeting siRNA ($p=0.43$, Wilcoxon matched pair sign test). C. Efficiency of knockdown with *BTNL2* vs non-targeting siRNA in dendritic cells used for A and B. 200ng of RNA from siRNA transfected cells was subjected to cDNA synthesis using a mix of oligo-dT-primer and random primer with the iScript cDNA synthesis Kit (Bio-Rad) followed by pre-amplification with gene specific primers and the SsoAdvanced PreAmp Supermix (Bio-Rad). qbase+-software (Biogazelle) was used for analysis of qPCR experiments. *BTNL2* expression was normalized to reference genes *TELO2* and *TRMT61A* and the Calibrated Normalized Relative Quantities (CNRQ) relative to the treatment with non-targeting siRNA is shown ($p=0.033$).


A CD45RA⁺ CD4⁺ T cell response to allogenic stimulus



B CD45RO⁺ CD4⁺ T cell response to recall antigen stimulus




C Efficiency of *BTNL2* knockdown




SUPPLEMENTARY DATA

Supplementary Figure 7. Risk of developing islet autoantibodies and diabetes in FDR children (B, D, F) and in GP children (A, B, C) according to genetic susceptibility strata based on *BTNL2* SNP rs3763305 and genetic risk score (GRS). Risks are shown for the development of one or more islet autoantibodies (A, B), multiple islet autoantibodies (C, D), and diabetes (E, F). All of the children had the *DR3/DR4-DQ8* or *DR4-DQ8/DR4-DQ8* genotype. Genetic susceptibility strata were defined as follows: 1. rs3763305 GG AND GRS in the upper quartile (red); 2. rs3763305 GG AND GRS in the second quartile, OR rs3763305 GA or AA AND GRS in the upper quartile (grey); 3. rs3763305 GG AND GRS in the lower 50th centile OR rs3763305 GA or AA AND GRS in the second quartile (green); and 4. rs3763305 GA or AA AND GRS in the lower 50th centile (blue). *P*-values were calculated across all strata using log-rank tests.



SUPPLEMENTARY DATA

Supplementary Figure 8. Risk of developing one or more islet autoantibodies (A, D, G, J), multiple islet autoantibodies (B, E, H, K) and diabetes (C, F, I, L) in children with a mother with T1D (red) compared with children with a father or sibling with T1D (blue). Children have been stratified by genetic risk score and HLA *DRB1*04* subtype into four risk strata from highest genetic susceptibility (A, B, C), to the lowest genetic susceptibility (J, K, L). *P*-values were calculated using log-rank tests.



SUPPLEMENTARY DATA

Supplementary Table 1. Genotype frequencies for SNPs used in the genetic risk score in FDR children and in GP children

SNP	Gene	Genotype frequency [%] *						P-value
		FDR children			GP children			
		PP	SP	SS	PP	SP	SS	
rs6897932	<i>IL7R</i>	11.8	34.5	53.7	7.7	41.0	51.3	0.0020
rs1004446	<i>INS</i>	9.0	44.7	46.3	14.4	45.6	40.0	0.0025
rs3825932	<i>CTSH</i>	10.9	40.0	49.2	13.9	44.1	42.1	0.014
rs3024505	<i>IL10</i>	2.4	20.9	76.8	2.2	27.0	70.8	0.025
rs3184504	<i>SH2B3</i>	27.4	46.8	25.8	30.9	48.8	20.3	0.027
rs2292239	<i>ERBB3</i>	42.8	44.0	13.2	46.4	44.1	9.6	0.043
rs1990760	<i>IFIH1</i>	13.5	50.1	36.3	18.3	47.4	34.3	0.053
rs10517086	<i>Unknown</i>	46.8	46.6	6.6	51.4	40.7	7.9	0.058
rs229541	<i>IL2B</i>	29.8	49.4	20.8	34.5	48.3	17.2	0.064
rs7804356	<i>SCAP2</i>	3.3	34.0	62.6	5.7	35.2	59.1	0.079
rs2069763	<i>IL2</i>	35.5	51.1	13.5	39.4	45.5	15.1	0.088
rs3757247	<i>BACH2</i>	28.9	48.6	22.5	33.2	47.7	19.1	0.10
rs4948088	<i>COBL</i>	0.2	5.9	93.9	0.3	8.8	90.9	0.12
rs7020673	<i>GLIS3</i>	21.7	47.3	31.0	24.4	49.0	26.5	0.12
rs2476601	<i>PTPN22</i>	76.1	22.5	1.4	80.3	18.6	1.1	0.12
rs2816316	<i>RGS1</i>	5.0	29.6	65.5	3.3	30.4	66.3	0.20
rs9388489	<i>C6ORF</i>	26.7	51.8	21.5	29.7	47.6	22.7	0.25
rs425105	<i>PRKD2</i>	1.4	28.6	70.0	2.7	27.1	70.2	0.26
rs45450798	<i>PTPN2</i>	66.7	29.3	4.0	69.6	27.5	2.9	0.26
rs5753037	<i>Unknown</i>	42.8	43.3	13.9	40.6	47.2	12.2	0.27
rs3087243	<i>CTLA4</i>	14.7	47.8	37.6	17.5	47.0	35.5	0.31
rs2395029	<i>HLA_B_5701</i>	0.0	1.2	98.8	0.0	2.2	97.7	0.32
rs17574546	<i>Unknown</i>	61.6	33.4	5.0	64.3	31.8	3.9	0.41
rs2281808	<i>SIRPG</i>	9.7	46.0	44.3	11.8	44.5	43.7	0.43
rs1465788	<i>ZFP36L1</i>	7.1	44.4	48.5	7.9	41.2	50.9	0.43
rs3788013	<i>UBASH3A</i>	35.9	50.1	13.9	35.0	48.6	16.4	0.44
rs4788084	<i>IL27</i>	17.5	47.8	34.8	19.4	48.3	32.3	0.50
rs763361	<i>CD226</i>	26.0	48.7	25.3	27.1	49.8	23.0	0.57
rs6920220	<i>TNFAIP3</i>	64.5	30.5	5.0	63.6	32.0	4.4	0.73
rs1738074	<i>TAGAP</i>	19.9	46.3	33.8	18.6	48.0	33.4	0.76
rs12708716	<i>CLEC16A</i>	12.6	42.2	45.3	12.2	44.0	43.8	0.76
rs7221109	<i>unknown</i>	13.9	44.2	41.8	13.6	45.9	40.4	0.79
rs2664170	<i>GAB3</i>	56.5	22.7	20.8	57.6	21.4	20.9	0.83
rs4763879	<i>CD69</i>	37.7	49.1	13.3	38.9	47.7	13.4	0.86
rs947474	<i>PRKCQ</i>	3.5	30.5	66.0	3.2	30.1	66.8	0.89
rs5979785	<i>TLR8</i>	17.5	18.4	64.1	18.2	18.5	63.3	0.92
rs7202877	<i>unknown</i>	79.7	19.1	1.2	79.1	19.5	1.3	0.95
rs1264813	<i>HLA_A_24</i>	82.7	16.6	0.7	82.3	17.0	0.7	0.98

SUPPLEMENTARY DATA

rs10509540	<i>C10orf59</i>	7.1	38.3	54.6	7.3	38.3	54.4	0.98
rs12722495	<i>IL2R</i>	0.7	16.5	82.7	0.7	16.6	82.7	1.00

* P refers to the protective allele and S refers to the susceptible allele

SUPPLEMENTARY DATA

Supplementary Table 2. Cox proportional hazards models for the development of islet autoantibodies and diabetes in FDR children compared with GP children in TEDDY children with the HLA *DR3/4-DQ8* genotype

Variable	One or more islet autoantibodies				Multiple islet autoantibodies				Diabetes			
	Model 1 *		Model 2 *		Model 1 *		Model 2 *		Model 1 *		Model 2 *	
	HR	P-value	HR	P-value	HR	P-value	HR	P-value	HR	P-value	HR	P-value
	(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)	
First-degree relative	2.24	<0.0001	1.95	<0.0001	2.92	<0.0001	2.47	<0.0001	3.48	<0.0001	2.86	<0.0001
	(1.67–3.01)		(1.45–2.63)		(2.09–4.07)		(1.76–3.46)		(2.30–5.28)		(1.88–4.36)	
<i>DRB1</i> *0401/x †			1.26	0.11			1.24	0.22			1.17	0.47
			(0.95–1.68)				(0.88–1.74)				(0.76–1.79)	
Genetic risk score ‡			1.50	<0.0001			1.63	<0.0001			1.56	<0.0001
			(1.33–1.68)				(1.41–1.88)				(1.29–1.87)	
<i>BTNL2</i> rs3763305 GG §			1.09	0.60			1.43	0.090			1.92	0.021
			(0.79–1.51)				(0.95–2.17)				(1.11–3.35)	
<i>ITGA1</i> rs7735139 GG §			1.26	0.20			1.14	0.56			1.25	0.43
			(0.88–1.82)				(0.73–1.80)				(0.72–2.18)	

* Model 1 and 2 are adjusted for sex, country (reference: US) and HLA genotype; † reference: *DRB1* without 0401 or 0401/0404 and 0401/0407; ‡ per unit increase; § reference: GA/AA genotype

SUPPLEMENTARY DATA

Supplementary Table 3. Genotype frequencies of *BTNL2* SNP rs3765503 in validation cohort

	BTNL2 rs3765503 genotype			P-value*
	GG	AG	AA	
Control	487 (71%)	200 (29%)	0 (0%)	<0.0001
Diabetes	3496 (81%)	842 (19%)	0 (0%)	

* P-value was calculated using Fisher's exact test.

The validation cohort consists of 5,025 Caucasian subjects with European decent and HLA *DR3/4-DQ8* genotype according to the algorithm defined by Barker et al. (2), which is based on the tag SNPs rs7454108 and rs2040410. Samples were genotyped on the Illumina ImmunoChip array and imputed to the TOPMed Reference Panel. rs3763305 was directly genotyped on the ImmunoChip. rs2040410, and rs7454108 were imputed with high confidence ($R^2 > 0.99$). Principal components were generated by calculating PC axes in unrelated controls using a set of 83,458 LD-pruned variants and projecting the remaining samples onto this PC space. A set of 33,249 European ancestry unrelated case-control subjects were identified for analysis by comparing PCs to 1000 Genomes Phase 3 subjects (3). We ensured samples were unrelated (less than second degree relationship) using KING version 2.13 (<http://people.virginia.edu/~wc9c/KING/>). 5,025 of these samples have the HLA *DR3/4-DQ8* genotype.

SUPPLEMENTARY DATA

Supplementary Table 4. Haplotypes of 34 SNPs in *BTNL2* and their frequencies in HLA *DR3/4-DQ8* and *DR4-DQ8/DR4-DQ8*. SNPs in bold are those that were identified as enriched within FDR children. Haplotype ID ‘X’ indicates that they are not among the 30 most frequent haplotypes.

frequency [%] in		Haplotype ID	rs3817969	rs3129953	rs28362678	rs2076530	rs9268480	rs2076529	rs9268481	rs3129954	rs3129955	rs4248166	rs2294884	rs2294883	rs2294882	rs2294881	rs2294880	rs9268482	rs2294878	rs3817966	rs3817964	rs3817963	rs3817962	rs3763305	rs2076525	rs2076523	rs2076522	rs3793127	rs10947260	rs10947261	rs10947262	rs3806155	rs3806156	rs3806157	rs2395158	rs3763307		
42.82	0.26	9	G	A	G	A	G	A	A	G	G	A	A	T	A	A	A	A	C	A	A	A	C	G	A	A	C	G	A	C	G	T	C	A	G	T		
18.12	18.70	25	G	G	G	G	A	G	G	G	G	A	A	T	A	A	G	T	A	G	A	G	A	G	G	G	G	A	A	C	G	A	A	C	A	A	A	
15.14	14.62	28	G	G	G	G	A	G	G	G	G	A	A	T	A	A	G	T	A	G	T	G	A	A	G	G	G	A	A	C	G	T	A	C	A	A	A	
12.48	12.29	26	G	G	G	G	A	G	G	G	G	A	A	T	A	A	G	T	A	G	A	G	A	G	G	G	G	A	A	C	G	T	A	C	A	A	A	
9.86	3.56	12	G	G	G	A	G	A	A	A	A	A	A	T	A	A	A	A	C	A	A	A	C	G	A	A	C	G	A	C	G	T	C	A	A	T	A	
0.60	0.09	27	G	G	G	G	A	G	G	G	G	A	A	T	A	A	G	T	A	G	A	G	A	G	G	G	G	G	A	C	G	T	A	C	A	A	A	
0.31	0.27	16	G	G	G	A	G	A	A	G	G	A	A	T	A	A	A	A	C	A	A	A	C	G	A	A	C	G	A	C	G	T	C	A	A	T	A	
0.26	0.07	5	A	G	A	G	G	G	A	G	G	G	C	A	G	G	A	A	A	A	A	A	C	G	A	G	C	G	G	A	A	T	A	C	A	T	A	
0.15	0.10	21	G	G	G	A	G	A	A	G	G	G	C	A	G	G	A	A	A	A	A	A	C	G	A	G	C	G	G	A	A	T	A	C	A	T	A	
0.09	0.03	4	A	G	A	G	G	G	A	G	G	G	C	A	G	G	A	A	A	A	A	A	C	G	A	A	C	G	A	C	G	T	C	A	A	T	A	
0.05	0.03	23	G	G	G	G	A	G	G	G	G	A	A	T	A	A	A	T	A	G	A	G	A	G	G	G	G	A	A	C	G	T	A	C	A	A	A	
0.00	0.07	3	A	G	A	G	G	G	A	G	G	A	A	A	G	G	G	A	C	G	A	G	C	G	A	G	C	G	A	A	A	T	A	A	A	T	A	
0.03	0.00	8	G	A	G	A	G	A	A	G	G	A	A	T	A	A	A	A	C	A	A	A	C	G	A	A	C	G	A	C	G	T	C	A	A	T	A	
0.03	0.00	13	G	G	G	A	G	A	A	A	A	A	A	T	G	G	A	A	A	A	A	A	C	G	A	G	C	G	G	A	A	T	A	C	A	T	A	
0.02	0.00	17	G	G	G	A	G	A	A	G	G	A	A	T	A	A	A	A	C	A	A	A	C	G	A	A	C	G	A	C	G	T	C	A	G	T	A	
0.00	0.00	1	A	A	A	G	G	G	A	G	G	G	C	A	G	G	A	A	A	A	A	A	C	G	A	G	C	G	G	A	A	T	A	C	A	T	A	
0.02	0.00	6	A	G	G	G	G	G	A	G	G	G	A	A	G	G	G	A	C	G	A	A	A	G	A	G	C	G	G	C	A	T	A	A	A	T	A	
0.00	0.02	10	G	A	G	A	G	A	A	G	G	A	A	T	G	G	A	A	A	A	T	A	C	A	A	G	C	G	A	A	T	A	C	A	T	A	A	
0.02	0.00	11	G	A	G	G	A	G	G	G	G	A	A	T	A	A	G	T	A	G	T	G	A	A	G	G	G	A	A	C	G	T	A	C	A	A	A	A
0.00	0.00	14	G	G	G	A	G	A	A	A	G	A	A	T	A	A	A	A	C	A	A	A	C	G	A	A	C	G	A	C	G	T	C	A	G	T	A	
0.00	0.00	15	G	G	G	A	G	A	A	G	A	A	A	T	A	A	A	A	C	A	A	A	C	G	A	A	C	G	A	C	G	T	C	A	A	T	A	
0.00	0.02	24	G	G	G	G	A	G	G	G	G	A	A	T	A	A	G	T	A	G	A	G	A	G	G	G	G	A	A	C	A	T	A	C	A	A	A	A
0.00	0.00	x	G	A	G	A	G	A	A	G	G	A	A	T	G	G	A	A	A	A	A	A	C	G	A	G	C	G	G	A	A	T	A	C	A	T	A	
0.00	0.00	x	G	G	G	A	G	A	A	G	G	G	C	A	G	G	A	A	A	A	T	A	C	A	A	G	C	A	G	A	A	T	A	C	A	T	A	

SUPPLEMENTARY DATA

Supplementary Table 5. Relationship between *BTNL2* SNP rs3765503 genotypes and HLA *DR3* and *DRB1*04* subtypes in children with the HLA *DR3/DR4-DQ8* genotype

HLA <i>DR</i> genotype	<i>BTNL2</i> rs3763305 genotype			Allele frequency (%)	
	AA	GA	GG	A	G
<i>DR3/DR3</i>	2 (0.1%)	9 (0.6%)	1608 (99.3%)	0.4	99.6
<i>DR3/DRB1*04:01</i>	0 (0.0%)	15 (1.0%)	1496 (99.0%)	0.5	99.5
<i>DR3/DRB1*04:02</i>	0 (0.0%)	2 (1.2%)	165 (98.8%)	0.6	99.4
<i>DR3/DRB1*04:04</i>	1 (0.1%)	837 (78.1%)	233 (21.8%)	39.2	60.8
<i>DR3/DRB1*04:05</i>	0 (0.0%)	0 (0.0%)	134 (100.0%)	0.0	100.0
<i>DR3/DRB1*04:06</i>	0 (0.0%)	1 (100.0%)	0 (0.0%)	50.0	50.0
<i>DR3/DRB1*04:07</i>	0 (0.0%)	33 (68.8%)	15 (31.2%)	34.4	65.6
<i>DR3/DRB1*04:08</i>	0 (0.0%)	1 (4.8%)	20 (95.2%)	2.4	97.6
<i>DR3/DRB1*04:10</i>	0 (0.0%)	0 (0.0%)	1 (100.0%)	0.0	100.0

Supplementary Table 6. Association of the *BTNL2* rs3763305 genotype with HLA *DRB1*04* subtype alleles in children with the HLA *DR3/DR4-DQ8* genotype from the Bavarian diabetes registry DiMelli

<i>DRB1*04</i> subtype	<i>BTNL2</i> rs3763305 genotype		
	AA	AG	GG
<i>DR3/DRB1*04:01</i>	0 (0.0%)	0 (0.0%)	89 (100.0%)
<i>DR3/DRB1*04:02</i>	0 (0.0%)	0 (0.0%)	21 (100.0%)
<i>DR3/DRB1*04:04</i>	0 (0.0%)	18 (75.0%)	6 (25.0%)
<i>DR3/DRB1*04:05</i>	0 (0.0%)	0 (0.0%)	7 (100.0%)

Supplementary Table 7. Cox proportional hazards models for developing one or more islet autoantibodies, multiple islet autoantibodies and diabetes according to *BTNL2* rs3763305 in children with the HLA *DR3/DRB1*0404-DQ8* or HLA *DRB1*0404-DQ8/DRB1*0404-DQ8* genotypes adjusted for the HLA *DR3/DR4-DQ8* genotype

	One or more islet autoantibodies		Multiple islet autoantibodies		Diabetes	
	HR	<i>P</i> -value	HR	<i>P</i> -value	HR	<i>P</i> -value
	(95% CI)		(95% CI)		(95% CI)	
HLA <i>DR3/DR4-DQ8</i> *	1.48 (0.81–2.70)	0.20	1.64 (0.70–3.82)	0.25	1.26 (0.44–3.59)	0.66
<i>BTNL2</i> rs3763305 GG †	1.13 (0.74–1.74)	0.57	1.49 (0.88–2.54)	0.14	2.38 (1.25–4.55)	0.0086

* Reference: *DR4-DQ8/DR4-DQ8*; † reference: GA/AA genotype

SUPPLEMENTARY DATA

Supplementary Table 8. Cumulative risk of developing islet autoantibodies or diabetes by 6 years old in children stratified by genetic risk score and HLA *DRB1*04* subtype

Risk strata	One or more islet autoantibodies		Multiple islet autoantibodies		Diabetes	
	GP children	FDR children	GP children	FDR children	GP children	FDR children
1: High-risk <i>DR4</i> * AND 1 st quartile GRS	17.4%	16.7%	12.7%	14.3%	4.1%	4.8%
	(13.6–21.2%)	(7.9–24.6%)	(9.3–16.0%)	(6.1–21.9%)	(2.2–5.9%)	(0.1–9.2%)
2: High-risk <i>DR4</i> AND 2 nd quartile GRS OR low-risk <i>DR4</i> * AND 1 st quartile GRS	11.9%	23.4%	9.0%	17.0%	4.1%	9.1%
	(9.6–14.1%)	(14.7–31.2%)	(7.0–10.9%)	(9.3–24.1%)	(2.8–5.3%)	(3.5–14.3%)
3: High-risk <i>DR4</i> AND GRS <50 th centile OR low-risk <i>DR4</i> AND 2 nd quartile GRS	8.2%	19.3%	4.5%	14.8%	1.5%	7.1%
	(6.7–9.7%)	(12.2–25.9%)	(3.3–5.7%)	(8.4–20.7%)	(0.9–2.2%)	(2.8–11.2%)
4: Low-risk <i>DR4</i> AND GRS <50 th centile	4.3%	11.1%	1.6%	9.2%	0.5%	1.6%
	(2.9–5.5%)	(2.3–19.1%)	(0.8–2.4%)	(1.2–16.6%)	(0.1–0.9%)	(0.0–4.8%)
<i>P</i> -value †	<0.0001	0.45	<0.0001	0.60	<0.0001	0.18

* High-risk *DR4* was defined as *DR3/DRB1*0401* or *DRB1*0401-DQ8/DR4* without 0404 or 0407, and low risk were all other genotypes; † *P*-values were calculated as log-rank tests per column over the four strata. GRS, genetic risk score

SUPPLEMENTARY DATA

Supplementary Table 9. Hazard ratios (HRs) and 95% CIs for developing one or more islet autoantibodies, multiple islet autoantibodies and diabetes in FDR children (FDR mother vs FDR father vs FDR sibling vs FDR multiplex), adjusted for sex, genetic factors (reference: *DR4-DQ8/DR4-DQ8*), and country (reference US)

	One or more islet autoantibodies		Multiple islet autoantibodies		Diabetes	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
FDR multiplex	1.94 (0.62–6.12)	0.26	3.37 (1.06–10.66)	0.039	5.90 (1.84–18.94)	0.0029
FDR mother	0.85 (0.50–1.44)	0.54	0.97 (0.52–1.79)	0.91	1.39 (0.67–2.87)	0.38
FDR father	2.37 (1.71–3.28)	<0.0001	2.89 (2.00–4.17)	<0.0001	3.06 (1.89–4.94)	<0.0001
FDR sibling	2.68 (1.70–4.22)	<0.0001	3.41 (2.07–5.62)	<0.0001	5.15 (2.94–9.03)	<0.0001
<i>DRB1</i> *04:01/x *	1.44 (1.11–1.86)	0.0057	1.49 (1.09–2.04)	0.012	1.40 (0.94–2.07)	0.096
Genetic risk score †	1.49 (1.35–1.65)	<0.0001	1.68 (1.48–1.90)	<0.0001	1.68 (1.43–1.98)	<0.0001
<i>BTNL2</i> rs3763305 GG ‡	1.02 (0.77–1.36)	0.88	1.34 (0.93–1.94)	0.12	1.74 (1.07–2.84)	0.026
<i>ITGA1</i> rs7735139 "GG" ‡	1.25 (0.91–1.73)	0.17	1.14 (0.76–1.72)	0.52	1.21 (0.72–2.03)	0.47

* Reference: *DRB1* without 0401 or 0401/0404 and 0401/0407; † per unit increase; ‡ reference: GA/AA genotype

SUPPLEMENTARY DATA

Supplemental Acknowledgements

The TEDDY Study Group

Colorado Clinical Center: Marian Rewers, M.D., Ph.D., PI^{1,4,5,6,10,11}, Kimberly Bautista¹², Judith Baxter^{9,10,12,15}, Daniel Felipe-Morales, Kimberly Driscoll, Ph.D.⁹, Brigitte I. Frohnert, M.D.^{2,14}, Marisa Gallant, M.D.¹³, Patricia Gesualdo^{2,6,12,14,15}, Michelle Hoffman^{12,13,14}, Rachel Karban¹², Edwin Liu, M.D.¹³, Jill Norris, Ph.D.^{2,3,12}, Adela Samper-Imaz, Andrea Steck, M.D.^{3,14}, Kathleen Waugh^{6,7,12,15}, Hali Wright¹². University of Colorado, Anschutz Medical Campus, Barbara Davis Center for Childhood Diabetes.

Finland Clinical Center: Jorma Toppari, M.D., Ph.D., PI^{¥1,4,11,14}, Olli G. Simell, M.D., Ph.D., Annika Adamsson, Ph.D.^{^12}, Suvi Ahonen^{*±§}, Heikki Hyöty, M.D., Ph.D.^{*±6}, Jorma Ilonen, M.D., Ph.D.^{¥13}, Sanna Jokipuu[^], Leena Karlsson[^], Miia Kähönen^{μ±}, Mikael Knip, M.D., Ph.D.^{*±5}, Mirva Koreasalo^{*±§2}, Kalle Kurppa, M.D., Ph.D.^{*±13}, Tiina Latva-aho^{μ±}, Maria Lönnrot, M.D., Ph.D.^{*±6}, Markus Mattila^{*}, Elina Mäntymäki[^], Katja Multasuo^{μ±}, Tiina Niininen^{*±12}, Sari Niinistö^{±§2}, Mia Nyblom^{*±}, Paula Ollikainen^{μ±}, Petra Rajala[^], Jenna Rautanen^{±§}, Anne Riikonen^{*±§}, Minna Romo[^], Suvi Ruohonen[^], Juulia Rönkä^{μ±}, Satu Simell, M.D., Ph.D.^{¥13}, Tuula Simell, Ph.D.^{¥12}, Maija Sjöberg^{¥12,14}, Aino Stenius^{μ±12}, Sini Vainionpää[^], Eeva Varjonen^{¥12}, Riitta Veijola, M.D., Ph.D.^{μ±14}, Suvi M. Virtanen, M.D., Ph.D.^{*±§2}, Mari Vähä-Mäkilä[^], Mari Åkerlund^{*±§}, Katri Lindfors, Ph.D.^{*13} ¥University of Turku, *University of Tampere, μUniversity of Oulu, ^Turku University Hospital, Hospital District of Southwest Finland, ±Tampere University Hospital, °Oulu University Hospital, §National Institute for Health and Welfare, Finland, ¥University of Kuopio.

Georgia/Florida Clinical Center: Jin-Xiong She, Ph.D., PI^{1,3,4,11}, Desmond Schatz, M.D.^{*4,5,7,8}, Diane Hopkins¹², Leigh Steed^{12,13,14,15}, Jennifer Bryant, Janey Adams^{*12}, Katherine Silvis², Michael Haller, M.D.^{*14}, Melissa Gardiner, Richard McIndoe, Ph.D., Ashok Sharma, Stephen W. Anderson, M.D.[^], Laura Jacobsen, M.D.^{*14}, John Marks, DHSc.^{*}, P.D. Towe^{*}. Center for Biotechnology and Genomic Medicine, Augusta University. *University of Florida, ^Pediatric Endocrine Associates, Atlanta.

Germany Clinical Center: Anette-G. Ziegler, M.D., PI^{1,3,4,11}, Andreas Beyerlein, Ph.D.², Ezio Bonifacio Ph.D.^{*5}, Anita Gavrisan, Cigdem Gezginci, Anja Heublein, Michael Hummel, M.D.¹³, Sandra Hummel, Ph.D.², Annette Knopff⁷, Charlotte Koch, Sibylle Koletzko, M.D.^{¶13}, Claudia Ramminger, Roswith Roth, Ph.D.⁹, Marlon Scholz, Joanna Stock^{9,12,14}, Katharina Warncke, M.D.¹⁴, Lorena Wendel, Christiane Winkler, Ph.D.^{2,12,15}. Forschergruppe Diabetes e.V. and Institute of Diabetes Research, Helmholtz Zentrum München, Forschergruppe Diabetes, Technische Universität München. *Center for Regenerative Therapies, TU Dresden, ¶Dr. von Hauner Children's Hospital, Department of Gastroenterology, Ludwig Maximilians University Munich.

Sweden Clinical Center: Åke Lernmark, Ph.D., PI^{1,3,4,5,6,8,10,11,15}, Daniel Agardh, M.D., Ph.D.¹³, Carin Andréon Aronsson, Ph.D.^{2,12,13}, Maria Ask, Jenny Bremer, Ulla-Marie Carlsson, Corrado Cilio, Ph.D., M.D.⁵, Emelie Ericson-Hallström, Annika Fors, Lina Fransson, Thomas Gard, Rasmus Bennet, Carina Hansson, Susanne Hyberg, Hanna Jisser, Fredrik Johansen, Berglind Jonsdottir, M.D., Ph.D., Silvija Jovic, Helena Elding Larsson, M.D., Ph.D.^{6,14}, Marielle Lindström, Markus Lundgren, M.D., Ph.D.¹⁴, Maria Månsson-Martinez, Maria Markan, Jessica Melin¹², Zeliha Mestan, Caroline Nilsson, Karin Ottosson, Kobra Rahmati, Anita Ramelius, Falastin Salami, Sara Sibthorpe, Anette Sjöberg, Birgitta Sjöberg, Carina Törn, Ph.D.^{3,15}, Anne Wallin, Åsa Wimar¹⁴, Sofie Åberg. Lund University.

Washington Clinical Center: William A. Hagopian, M.D., Ph.D., PI^{1,3,4,5,6,7,11,13,14}, Michael Killian^{6,7,12,13}, Claire Cowen Crouch^{12,14,15}, Jennifer Skidmore², Ashley Akramoff, Jana Banjanin, Masumeh Chavoshi, Kayleen Dunson, Rachel Hervey, Rachel Lyons, Arlene Meyer, Denise Mulenga, Jared Radtke, Davey Schmitt, Julie Schwabe, Sarah Zink. Pacific Northwest Research Institute.

Pennsylvania Satellite Center: Dorothy Becker, M.D., Margaret Franciscus, MaryEllen Dalmagro-Elias Smith², Ashi Daftary, M.D., Mary Beth Klein, Chrystal Yates. Children's Hospital of Pittsburgh of UPMC.

Data Coordinating Center: Jeffrey P. Krischer, Ph.D., PI^{1,4,5,10,11}, Sarah Austin-Gonzalez, Maryouri Avendano, Sandra Baethke, Rasheedah Brown^{12,15}, Brant Burkhardt, Ph.D.^{5,6}, Martha Butterworth², Joanna Clasen, David Cuthbertson, Christopher Eberhard, Steven Fiske⁹, Dena Garcia, Jennifer Garmeson, Veena Gowda, Kathleen Heyman, Belinda Hsiao, Francisco Perez Laras, Hye-Seung Lee, Ph.D.^{1,2,13,15}, Shu Liu, Xiang Liu, Ph.D.^{2,3,9,14}, Kristian Lynch, Ph.D.^{5,6,9,15}, Colleen Maguire, Jamie Malloy, Cristina McCarthy^{12,15}, Aubrie Merrell, Steven Meulemans, Hemang Parikh, Ph.D.³, Ryan Quigley, Cassandra Remedios, Chris Shaffer, Laura Smith, Ph.D.^{9,12}, Susan Smith^{12,15}, Noah Sulman, Ph.D., Roy Tamura, Ph.D.^{1,2,13}, Ulla Uusitalo, Ph.D.^{2,15}, Kendra Vehik,

SUPPLEMENTARY DATA

Ph.D.^{4,5,6,14,15}, Ponni Vijayakandipan, Keith Wood, Jimin Yang, Ph.D., R.D.^{2,15}. *Past staff: Michael Abbondandolo, Lori Ballard, David Hadley, Ph.D., Wendy McLeod.* University of South Florida.

Project scientist: Beena Akolkar, Ph.D.^{1,3,4,5,6,7,10,11}. National Institutes of Diabetes and Digestive and Kidney Diseases.

Other contributors: Kasia Bourcier, Ph.D.⁵, National Institutes of Allergy and Infectious Diseases. Thomas Briese, Ph.D.^{6,15}, Columbia University. Suzanne Bennett Johnson, Ph.D.^{9,12}, Florida State University. Eric Triplett, Ph.D.⁶, University of Florida.

Autoantibody Reference Laboratories: Liping Yu, M.D.⁵, Dongmei Miao, M.D.⁵, Polly Bingley, M.D., FRCP⁵, Alistair Williams*, Kyla Chandler*, Olivia Ball*, Ilana Kelland*, Sian Grace*, Ben Gillard*. ⁵Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, *Bristol Medical School, University of Bristol UK.

HLA Reference Laboratory: William Hagopian³, MD, PhD, Masumeh Chavoshi, Jared Radtke, Julie Schwabe. Pacific Northwest Research Institute, Seattle WA. (Previously Henry Erlich, Ph.D.³, Steven J. Mack, Ph.D., Anna Lisa Fear. Center for Genetics, Children's Hospital Oakland Research Institute.)

SNP Laboratory: Stephen S. Rich, Ph.D.³, Wei-Min Chen, Ph.D.³, Suna Onengut-Gumuscu, Ph.D.³, Emily Farber, Rebecca Roche Pickin, Ph.D., Jonathan Davis, Jordan Davis, Dan Gallo, Jessica Bonnie, Paul Campolieto. Center for Public Health Genomics, University of Virginia.

Repository: Sandra Ke, Niveen Mulholland, Ph.D. NIDDK Biosample Repository at Fisher BioServices.

Committees: ¹Ancillary Studies, ²Diet, ³Genetics, ⁴Human Subjects/Publicity/Publications, ⁵Immune Markers, ⁶Infectious Agents, ⁷Laboratory Implementation, ⁸Maternal Studies, ⁹Psychosocial, ¹⁰Quality Assurance, ¹¹Steering, ¹²Study Coordinators, ¹³Celiac Disease, ¹⁴Clinical Implementation, ¹⁵Quality Assurance Subcommittee on Data Quality.

Supplemental References

1. Troegeler A, Lastrucci C, Duval C, Tanne A, Cougoule C, Maridonnoeu-Parini I, Neyrolles O, Lugo-Villarino G: An efficient siRNA-mediated gene silencing in primary human monocytes, dendritic cells and macrophages. *Immunol Cell Biol* 2014;92:699-708
2. Barker JM, Triolo TM, Aly TA, Baschal EE, Babu SR, Kretowski A, Rewers MJ, Eisenbarth GS: Two single nucleotide polymorphisms identify the highest-risk diabetes HLA genotype: potential for rapid screening. *Diabetes* 2008;57:3152-3155
3. The Genomes Project C, Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark AG, Donnelly P, Eichler EE, Flicek P, Gabriel SB, Gibbs RA, Green ED, Hurles ME, Knoppers BM, Korbel JO, Lander ES, Lee C, Lehrach H, Mardis ER, Marth GT, McVean GA, Nickerson DA, Schmidt JP, Sherry ST, Wang J, Wilson RK, Gibbs RA, Boerwinkle E, Doddapaneni H, Han Y, Korchina V, Kovar C, Lee S, Muzny D, Reid JG, Zhu Y, Wang J, Chang Y, Feng Q, Fang X, Guo X, Jian M, Jiang H, Jin X, Lan T, Li G, Li J, Li Y, Liu S, Liu X, Lu Y, Ma X, Tang M, Wang B, Wang G, Wu H, Wu R, Xu X, Yin Y, Zhang D, Zhang W, Zhao J, Zhao M, Zheng X, Lander ES, Altshuler DM, Gabriel SB, Gupta N, Gharani N, Toji LH, Gerry NP, Resch AM, Flicek P, Barker J, Clarke L, Gil L, Hunt SE, Kelman G, Kulesha E, Leinonen R, McLaren WM, Radhakrishnan R, Roa A, Smirnov D, Smith RE, Streeter I, Thormann A, Toneva I, Vaughan B, Zheng-Bradley X, Bentley DR, Grocock R, Humphray S, James T, Kingsbury Z, Lehrach H, Sudbrak R, Albrecht MW, Amstislavskiy VS, Borodina TA, Lienhard M, Mertes F, Sultan M, Timmermann B, Yaspo M-L, Mardis ER, Wilson RK, Fulton L, Fulton R, Sherry ST, Ananiev V, Belaia Z, Beloslyudtsev D, Bouk N, Chen C, Church D, Cohen R, Cook C, Garner J, Hefferon T, Kimelman M, Liu C, Lopez J, Meric P, O'Sullivan C, Ostapchuk Y, Phan L, Ponomarov S, Schneider V, Shekhtman E, Sirotkin K, Slotta D, Zhang H, McVean GA, Durbin RM, Balasubramaniam S, Burton J, Danecek P, Keane TM, Kolb-Kokocinski A, McCarthy S, Stalker J, Quail M, Schmidt JP, Davies CJ, Gollub J, Webster T, Wong B, Zhan Y, Auton A, Campbell CL, Kong Y, Marcketta A, Gibbs RA, Yu F, Antunes L, Bainbridge M, Muzny D, Sabo A, Huang Z, Wang J, Coin LJM, Fang L, Guo X, Jin X, Li G, Li Q, Li Y, Li Z, Lin H, Liu B, Luo R, Shao H, Xie Y, Ye C, Yu C, Zhang F, Zheng H, Zhu H, Alkan C, Dal E, Kahveci F, Marth GT, Garrison EP, Kural D, Lee W-P, Fung Leong W, Stromberg M, Ward AN, Wu J, Zhang M, Daly MJ, DePristo MA, Handsaker RE, Altshuler DM, Banks E, Bhatia G, del Angel G, Gabriel SB, Genovese G, Gupta N, Li H, Kashin S, Lander ES, McCarroll SA, Nemesh JC, Poplin RE, Yoon SC, Lihm J, Makarov V, Clark AG, Gottipati S, Keinan A, Rodriguez-Flores JL, Korbel JO, Rausch T, Fritz MH, Stütz AM,

SUPPLEMENTARY DATA

Flicek P, Beal K, Clarke L, Datta A, Herrero J, McLaren WM, Ritchie GRS, Smith RE, Zerbino D, Zheng-Bradley X, Sabeti PC, Shlyakhter I, Schaffner SF, Vitti J, Cooper DN, Ball EV, Stenson PD, Bentley DR, Barnes B, Bauer M, Keira Cheetham R, Cox A, Eberle M, Humphray S, Kahn S, Murray L, Peden J, Shaw R, Kenny EE, Batzer MA, Konkel MK, Walker JA, MacArthur DG, Lek M, Sudbrak R, Amstislavskiy VS, Herwig R, Mardis ER, Ding L, Koboldt DC, Larson D, Ye K, Gravel S, Swaroop A, Chew E, Lappalainen T, Erlich Y, Gymrek M, Frederick Willems T, Simpson JT, Shriver MD, Rosenfeld JA, Bustamante CD, Montgomery SB, De La Vega FM, Byrnes JK, Carroll AW, DeGorter MK, Lacroute P, Maples BK, Martin AR, Moreno-Estrada A, Shringarpure SS, Zakharia F, Halperin E, Baran Y, Lee C, Cerveira E, Hwang J, Malhotra A, Plewczynski D, Radew K, Romanovitch M, Zhang C, Hyland FCL, Craig DW, Christoforides A, Homer N, Izatt T, Kurdoglu AA, Sinari SA, Squire K, Sherry ST, Xiao C, Sebat J, Antaki D, Gujral M, Noor A, Ye K, Burchard EG, Hernandez RD, Gignoux CR, Haussler D, Katzman SJ, James Kent W, Howie B, Ruiz-Linares A, Dermitzakis ET, Devine SE, Abecasis GR, Min Kang H, Kidd JM, Blackwell T, Caron S, Chen W, Emery S, Fritsche L, Fuchsberger C, Jun G, Li B, Lyons R, Scheller C, Sidore C, Song S, Sliwerska E, Taliun D, Tan A, Welch R, Kate Wing M, Zhan X, Awadalla P, Hodgkinson A, Li Y, Shi X, Quitadamo A, Lunter G, McVean GA, Marchini JL, Myers S, Churchhouse C, Delaneau O, Gupta-Hinch A, Kretzschmar W, Iqbal Z, Mathieson I, Menelaou A, Rimmer A, Xifara DK, Oleksyk TK, Fu Y, Liu X, Xiong M, Jorde L, Witherspoon D, Xing J, Eichler EE, Browning BL, Browning SR, Hormozdiari F, Sudmant PH, Khurana E, Durbin RM, Hurler ME, Tyler-Smith C, Albers CA, Ayub Q, Balasubramanian S, Chen Y, Colonna V, Danecek P, Jostins L, Keane TM, McCarthy S, Walter K, Xue Y, Gerstein MB, Abyzov A, Balasubramanian S, Chen J, Clarke D, Fu Y, Harmani AO, Jin M, Lee D, Liu J, Jasmine Mu X, Zhang J, Zhang Y, Li Y, Luo R, Zhu H, Alkan C, Dal E, Kahveci F, Marth GT, Garrison EP, Kural D, Lee W-P, Ward AN, Wu J, Zhang M, McCarroll SA, Handsaker RE, Altshuler DM, Banks E, del Angel G, Genovese G, Hartl C, Li H, Kashin S, Nemesi JC, Shakir K, Yoon SC, Lihm J, Makarov V, Degenhardt J, Korbel JO, Fritz MH, Meiers S, Raeder B, Rausch T, Stütz AM, Flicek P, Paolo Casale F, Clarke L, Smith RE, Stegle O, Zheng-Bradley X, Bentley DR, Barnes B, Keira Cheetham R, Eberle M, Humphray S, Kahn S, Murray L, Shaw R, Lameijer E-W, Batzer MA, Konkel MK, Walker JA, Ding L, Hall I, Ye K, Lacroute P, Lee C, Cerveira E, Malhotra A, Hwang J, Plewczynski D, Radew K, Romanovitch M, Zhang C, Craig DW, Homer N, Church D, Xiao C, Sebat J, Antaki D, Bafna V, Michaelson J, Ye K, Devine SE, Gardner EJ, Abecasis GR, Kidd JM, Mills RE, Dayama G, Emery S, Jun G, Shi X, Quitadamo A, Lunter G, McVean GA, Chen K, Fan X, Chong Z, Chen T, Witherspoon D, Xing J, Eichler EE, Chaisson MJ, Hormozdiari F, Huddleston J, Malig M, Nelson BJ, Sudmant PH, Parrish NF, Khurana E, Hurler ME, Blackburne B, Lindsay SJ, Ning Z, Walter K, Zhang Y, Gerstein MB, Abyzov A, Chen J, Clarke D, Lam H, Jasmine Mu X, Sisu C, Zhang J, Zhang Y, Gibbs RA, Yu F, Bainbridge M, Challis D, Evani US, Kovar C, Lu J, Muzny D, Nagaswamy U, Reid JG, Sabo A, Yu J, Guo X, Li W, Li Y, Wu R, Marth GT, Garrison EP, Fung Leong W, Ward AN, del Angel G, DePristo MA, Gabriel SB, Gupta N, Hartl C, Poplin RE, Clark AG, Rodriguez-Flores JL, Flicek P, Clarke L, Smith RE, Zheng-Bradley X, MacArthur DG, Mardis ER, Fulton R, Koboldt DC, Gravel S, Bustamante CD, Craig DW, Christoforides A, Homer N, Izatt T, Sherry ST, Xiao C, Dermitzakis ET, Abecasis GR, Min Kang H, McVean GA, Gerstein MB, Balasubramanian S, Habegger L, Yu H, Flicek P, Clarke L, Cunningham F, Dunham I, Zerbino D, Zheng-Bradley X, Lage K, Berg J, Jaspersen J, Horn H, Montgomery SB, DeGorter MK, Khurana E, Tyler-Smith C, Chen Y, Colonna V, Xue Y, Gerstein MB, Balasubramanian S, Fu Y, Kim D, Auton A, Marcketta A, Desalle R, Narechania A, Wilson Sayres MA, Garrison EP, Handsaker RE, Kashin S, McCarroll SA, Rodriguez-Flores JL, Flicek P, Clarke L, Zheng-Bradley X, Erlich Y, Gymrek M, Frederick Willems T, Bustamante CD, Mendez FL, David Poznik G, Underhill PA, Lee C, Cerveira E, Malhotra A, Romanovitch M, Zhang C, Abecasis GR, Coin L, Shao H, Mittelman D, Tyler-Smith C, Ayub Q, Banerjee R, Cerezo M, Chen Y, Fitzgerald TW, Louzada S, Massaia A, McCarthy S, Ritchie GR, Xue Y, Yang F, Gibbs RA, Kovar C, Kalra D, Hale W, Muzny D, Reid JG, Wang J, Dan X, Guo X, Li G, Li Y, Ye C, Zheng X, Altshuler DM, Flicek P, Clarke L, Zheng-Bradley X, Bentley DR, Cox A, Humphray S, Kahn S, Sudbrak R, Albrecht MW, Lienhard M, Larson D, Craig DW, Izatt T, Kurdoglu AA, Sherry ST, Xiao C, Haussler D, Abecasis GR, McVean GA, Durbin RM, Balasubramanian S, Keane TM, McCarthy S, Stalker J, Chakravarti A, Knoppers BM, Abecasis GR, Barnes KC, Beiswanger C, Burchard EG, Bustamante CD, Cai H, Cao H, Durbin RM, Gerry NP, Gharani N, Gibbs RA, Gignoux CR, Gravel S, Henn B, Jones D, Jorde L, Kaye JS, Keinan A, Kent A, Kerasidou A, Li Y, Mathias R, McVean GA, Moreno-Estrada A, Ossorio PN, Parker M, Resch AM, Rotimi CN, Royal CD, Sandoval K, Su Y, Sudbrak R, Tian Z, Tishkoff S, Toji LH, Tyler-Smith C, Via M, Wang Y, Yang H, Yang L, Zhu J, Bodmer W, Bedoya G, Ruiz-Linares A, Cai Z, Gao Y, Chu J, Peltonen L, Garcia-Montero A, Orfao A, Dutil J, Martinez-Cruzado JC, Oleksyk TK, Barnes KC, Mathias RA, Hennis A, Watson H, McKenzie C, Qadri F, LaRocque R, Sabeti PC, Zhu J, Deng X, Sabeti PC, Asogun D, Folarin O, Happi C, Omoniwa O, Stremlau M, Tariyal R, Jallow M, Sisay Joof F, Corrah T, Rockett K, Kwiatkowski D, Kooner J, Tinh Hiê'n Tn, Dunstan SJ, Thuy Hang N, Fannie R, Garry R, Kanneh L, Moses L, Sabeti PC, Schieffelin J, Grant DS, Gallo C, Poletti G, Saleheen D, Rasheed A, Brooks LD, Felsenfeld AL, McEwen JE, Vaydylevich Y, Green ED, Duncanson A, Dunn M, Schloss JA, Wang J, Yang H, Auton A, Brooks LD, Durbin RM, Garrison EP, Min Kang H, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR: A global reference for human genetic variation. *Nature* 2015;526:68